MRC Clinical Research Professorship

Lead Research Organisation: University of Southampton
Department Name: Medicine

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Publications

10 25 50
publication icon
An SS (2016) An inflammation-independent contraction mechanophenotype of airway smooth muscle in asthma. in The Journal of allergy and clinical immunology

publication icon
Belvisi MG (2016) The ever-expanding ERS fellowship programmes: achievements over the past 3 years. in The European respiratory journal

publication icon
Brozek JL (2010) Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. in The Journal of allergy and clinical immunology

publication icon
Burkart KM (2006) Association of asthma with a functional promoter polymorphism in the IL16 gene. in The Journal of allergy and clinical immunology

publication icon
Campbell-Harding G (2013) The innate antiviral response upregulates IL-13 receptor a2 in bronchial fibroblasts. in The Journal of allergy and clinical immunology

 
Description Advice to the Public on Acute Air Pollution Episodes
Geographic Reach National 
Policy Influence Type Citation in other policy documents
Impact We used new research to redefine the threholds for medical advice on air pollution episodes in the UK. This was a COMEAP Subgroup that I chaired.
URL https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/304633/COMEAP_review_of_th...
 
Description Advisory Committee for Hazardous Substances (ACHS, Defra)
Geographic Reach Europe 
Policy Influence Type Participation in a advisory committee
Impact Advice to Government and the public on chemical regulation.
URL https://www.gov.uk/government/groups/hazardous-substances-advisory-committee
 
Description Advisory Committeeon Novel Foods and Processes
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
Impact Protection of the public through regulation and labelling. I completed my term in 2014
URL http://acnfp.food.gov.uk/
 
Description Board Chair NC3Rs
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
Impact NC3Rs Board Chair appointed by interview. Help in setting the straegic diection of NC3Rs and implement the different grants panels and forms of funding (e.g.CrackIt)
URL https://www.nc3rs.org.uk/about-us/board
 
Description Board of Management of the World Allergy Organisation.
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in a advisory committee
Impact Many outputs, but mostly organising and advising on international activities in Allergy (including its recognition as a public healthy problem). After being a Board member for 4 years I was selected to be Treasurer that I did for a further 2 years before demitting.
URL http://www.worldallergy.org/
 
Description Committee for the Medical Effects of Air Pollutants
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
Impact Policy relating to Air Quality and advice to the public. I was Founder Chair for 15 years and then Chaired Defra's EPAQS that became subsumed into COMEAP as its Standards Quality Subgroup.
URL https://www.gov.uk/government/groups/committee-on-the-medical-effects-of-air-pollutants-comeap
 
Guideline Title Asthma Management Guidelines 2008
Description Inflammation as the basis of asthma
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact Better treatment of asthma.
URL http://www.ginasthma.org/
 
Guideline Title Global Innitiative for Asthma
Description Inflammation as underlying the need for controller drugs in asthma management
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact Better asthma diagnosis and treatment.
URL http://www.ginasthma.org/
 
Description Member of the Royal Commission on Environmental Pollution
Geographic Reach Europe 
Policy Influence Type Citation in other policy documents
Impact 10 Reports on a vast range of topics including chemicals, the urban environment, the oceons, pesticides, light pollution, biomass etc.
URL http://www.thenbs.com/PublicationIndex/Documents?Pub=RCEP
 
Description RCP/RCPH Report on Air Pollution
Geographic Reach National 
Policy Influence Type Citation in other policy documents
Impact This influential report has created new air quality initiatives in PHE, Defra and local authorities.
URL https://www.rcplondon.ac.uk/projects/outputs/every-breath-we-take-lifelong-impact-air-pollution
 
Description Special Advisor to the HOLSC on S & T
Geographic Reach National 
Policy Influence Type Gave evidence to a government review
Impact The Report will be published in Feb 2010.
URL http://www.publications.parliament.uk/pa/ld200910/ldselect/ldsctech/22/2202.htm
 
Description Translational Medicine Board (OSCHR)
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
 
Description Clinician Scientist
Amount £992,869 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 12/2009 
End 11/2013
 
Description MRC Capacity Buildiing Studentship
Amount £60,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 10/2006 
End 09/2009
 
Description MRC Clinician Scientist
Amount £1,000,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 02/2009 
End 03/2014
 
Description MRC PhD Studentship
Amount £60,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 10/2007 
End 09/2011
 
Description MRC PhD Studentship (ITTP)
Amount £60,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 10/2009 
End 09/2013
 
Description MRC Programme Grant
Amount £1,579,270 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 10/2008 
End 10/2013
 
Description MRC project grant
Amount £675,116 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 10/2006 
End 07/2010
 
Description NC3R's Project Grant
Amount £298,000 (GBP)
Organisation National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) 
Sector Private
Country United Kingdom
Start 04/2008 
End 07/2010
 
Description NIHR Biomedical Research Unit (Respiratory Disease)
Amount £7,000,000 (GBP)
Organisation National Institute for Health Research 
Department NIHR Southampton Respiratory Biomedical Research Centre
Sector Academic/University
Country United Kingdom
Start 01/2012 
End 12/2016
 
Description NIHR Biomedical Research Unit (Respiratory Disease)
Amount £7,000,000 (GBP)
Organisation National Institute for Health Research 
Department NIHR Southampton Respiratory Biomedical Research Centre
Sector Academic/University
Country United Kingdom
Start 10/2011 
End 09/2016
 
Description NIHR Senior Investigator
Amount £75,000 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 01/2011 
End 01/2016
 
Description Project grant
Amount £499,713 (GBP)
Organisation National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) 
Sector Private
Country United Kingdom
Start 01/2011 
End 06/2013
 
Description project grant
Amount £143,553 (GBP)
Funding ID 06/053 
Organisation Asthma UK 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description Asthma genetics 
Organisation University of Groningen
Country Netherlands 
Sector Academic/University 
PI Contribution Novel genes identified associated with asthma.
Collaborator Contribution Joint studentship exchange.
Impact Publications 19729670 . Also a long term relationship between Southampton and Groningen on PhD student exchanges.
Start Year 2007
 
Description Asthma genetics 
Organisation University of Nottingham
Department School of Molecular Medical Sciences Nottingham
Country United Kingdom 
Sector Academic/University 
PI Contribution Novel asthma genes;
Collaborator Contribution Joint publication
Impact Joint publications; 19443020
Start Year 2007
 
Description Asthma genetics with Profs Meyers and Bleecker, Wake Forest University 
Organisation Wake Forest University
Department Centre for Genomics and Personalised Medicine Research
Country United States 
Sector Academic/University 
PI Contribution Collaboration for research and exchange of materials
Collaborator Contribution Collaboration for research and exchange of materials
Impact Review in press in Lancet respiratory medicine Sessions at the ERS, EAACI and ATS Congresses
Start Year 2012
 
Description CD48 as a novel therapeutic target for asthma 
Organisation Hebrew University of Jerusalem
Department Faculty of Medicine
Country Israel 
Sector Academic/University 
PI Contribution We are exploring the role of CD48 as a key regulator of mast cell and eosinophil function in collaboration with Prof Franesco Levi-Schaffer.
Collaborator Contribution They have identified the target and we are assisting in validating it in human disease.
Impact We have already discussed development of blocking mAbs against CD48 with MRCT. They requested further validation which we are undertaking.
Start Year 2010
 
Description Clinical trial of interferon beta in asthma 
Organisation Manchester University NHS Foundation Trust
Department Respiratory Clinical Research Centre, Wythenshawe
Country United Kingdom 
Sector Public 
PI Contribution Identification of a lesion of beta interferon deficiency in asthmatic airways. Repacement with inhaled beta interferon in progress as a Phase 2 Clinical Trial.
Collaborator Contribution Professor Woodcock and colleagues are conducting a clinical trial funded by our company Synairgen
Impact Trial still in progress
Start Year 2009
 
Description Genetic control of asthma 
Organisation University of Cincinnati
Department Respiratory Research Cincinnati
Country United States 
Sector Academic/University 
PI Contribution Generated conditional gene manipulated mice (via an MRC Clinician Scientist award)
Collaborator Contribution Helped us develop tradgenic mice for ADAM33 and epithelial research in asthma
Impact Publications.
Start Year 2010
 
Description Genetics of asthma 
Organisation Wake Forest University
Department Department of Genetics
Country United States 
Sector Academic/University 
PI Contribution Collaboration relating to data and sample exchange
Collaborator Contribution Intellectual, exchange visits and exchange of clinical data and samples for genetic studies.Exchange of samples and clinical data
Impact Participation in a grant proposal in MRC Strastified Medicine Innitiative.
Start Year 2011
 
Description Genetics of asthma 
Organisation Wake Forest University
Department Department of Genetics
Country United States 
Sector Academic/University 
PI Contribution Collaboration relating to data and sample exchange
Collaborator Contribution Intellectual, exchange visits and exchange of clinical data and samples for genetic studies.Exchange of samples and clinical data
Impact Participation in a grant proposal in MRC Strastified Medicine Innitiative.
Start Year 2011
 
Description Meigunyah Destinguished Visiting Fellowship 
Organisation University of Melbourne
Department Department of Pharmacology
Country Australia 
Sector Academic/University 
PI Contribution Although the innitial collaboration with Professors Alastair Stewart and Garry Anderson, began 1n 2010, the award to me of this prestigeous Fellowship is enabling collaborative reserch and staff exchange with the University of Melbourne
Collaborator Contribution We have been working together to launch a nw Lung Centre in Melbourne, This will be anounced at the Public Lecture which is part of this Fellowship.
Impact None at present but anticipated
Start Year 2012
 
Description Norwich Medical School 
Organisation University of East Anglia
Department School of Medicine UEA
Country United Kingdom 
Sector Academic/University 
PI Contribution Member of the Med Sch Scientific Advisory Board (Chair Sir Nicholas Wright)
Collaborator Contribution One way at present
Impact Reports to Medical School
Start Year 2012
 
Description Translational medicine at Manchester 
Organisation University of Manchester
Department Manchester Academic Health Science Centre
Country United Kingdom 
Sector Academic/University 
PI Contribution Helped Manchester University shape and prioritise its translational medicine programmes. I was awarded a 3 year Visiting Professorship to do this
Collaborator Contribution It has been largely my helping them.
Impact Appointment of a new Chair in Translational Medicine
Start Year 2012
 
Title ANTI-VIRUS THERAPY FOR RESPIRATORY DISEASES 
Description Interferon treatment of asthma and COPD 
IP Reference JP2007528890 
Protection Patent application published
Year Protection Granted 2007
Licensed Yes
Impact Synairgen conducting Phase 2 Clinical Trials. Now oulicensed to AZ ($230 million) see: http://www.synairgen.com/news/press-releases/2014/astrazeneca-licence-deal/
 
Title Anti-virus therapy for respiratory diseases 
Description Inhaled interferon treatment in respiratory disese caused by viruses 
IP Reference US20070134763 
Protection Patent application published
Year Protection Granted 2007
Licensed Yes
Impact Clinical trials in progress with Synairgen
 
Title Anti-virus therapy for respiratory diseases 
Description Inhaled interfron for asthma and COPD 
IP Reference US7569216 
Protection Patent granted
Year Protection Granted 2009
Licensed Yes
Impact Clinical trials in progress with Synairgen.
 
Title INTERFERON-BETA FOR ANTI-VIRUS THERAPY FOR RESPIRATORY DISEASES 
Description INTERFERON-BETA FOR ANTI-VIRUS THERAPY FOR RESPIRATORY DISEASES 
IP Reference WO2005087253 
Protection Patent application published
Year Protection Granted
Licensed Yes
Impact Inhaled inteferon treatment of asthma and COPD
 
Title INTERFERON-BETA FOR ANTI-VIRUS THERAPY FOR RESPIRATORY DISEASES 
Description Inhaled interferon for asthma and COPD 
IP Reference WO2005087253 
Protection Patent application published
Year Protection Granted 2010
Licensed Yes
Impact Synairgen conducting clinical trials
 
Title INTERFERON-BETA FOR ANTI-VIRUS THERAPY FOR RESPIRATORY DISEASES 
Description Interfron by inhalation for lung diseases caused by viruses 
IP Reference JP2011144201 
Protection Patent application published
Year Protection Granted 2011
Licensed Yes
Impact Clinical trials in progress with Synairgen.
 
Title INTERFERON-beta FOR ANTI-VIRUS THERAPY FOR RESPIRATORY DISEASE 
Description Inhaled interferon beta for asthma and COPD exacerbations 
IP Reference JP2011144201 
Protection Patent application published
Year Protection Granted 2011
Licensed Yes
Impact Synairgen are conducting Phase 2 clinical trials.
 
Title Interferon beta in the treatment of exacerbations of asthma and COPD 
Description ANTI-VIRUS THERAPY FOR RESPIRATORY DISEASES: inhaled beta interferon for asthma exacerbations and COPD. 
IP Reference WO2005087253 
Protection Patent granted
Year Protection Granted
Licensed Yes
Impact Clinical Trial (Phase 2) in progress tpo be completed Dec 2011
 
Title Interferon beta 
Description We founded Synairgen in 2005 with a subsequent launch on AIM. Our recent (2009) fund raising will provide resource to take us through Phase 2 for IFN in asthma, Copd exacerbations and influenzaandemics. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2006
Development Status Under active development/distribution
Impact A new therapy of inhalede IFN for asthma, COPD and influenza independant of drug resistence. 
 
Company Name Synairgen 
Description New treatments for asthma and COPD. http://www.synairgen.com/ 
Year Established 2004 
Impact In haled Interferon beta trials for asthma, COPD and influenza. Biomarkers and biobank
Website http://www.synairgen.com
 
Company Name Synairgen 
Description Synairgen is a drug discovery and development company specialising in respiratory diseases with a focus on asthma and chronic obstructive pulmonary disease (COPD). It was spun out of the University of Southampton in 2003. A small lean and highly focused company to develop new respiratory drugs. Most of our effort is now focused on an inhaled formulation of IFN beta for treating severe virus-induced exacerbations of asthma and COPD as well as hospital-based influenza admissions.; http://www.synairgen.com/ 
Impact Successful preclinical and Phase 1 development of inhaled interferon beta for treatment of virus-induced asthma exacerbations. We are entering phase 2a for asthma and COPD indications after a successful 2nd fund raising round in early 2009.
Website http://www.synairgen.com
 
Description Charity Newsletter 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Primary Audience Public/other audiences
Results and Impact Uptake of more individuals into Clinical Trials

Local input into press
Year(s) Of Engagement Activity 2006,2007,2008,2009,2010
 
Description EU Parliament : Brussels Declaration on Asthma. 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Primary Audience Policymakers/politicians
Results and Impact Wporked with an MEP to bring together patient organisations, professionals and the industry to agree new and needed directions for asthma management.

Influennce over Management Guidelines.
Year(s) Of Engagement Activity 2007
 
Description Established AAIR Charity (Founder) 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Primary Audience Public/other audiences
Results and Impact Multiple interactions at public lectures and schools; charitable fund raising activities also.

Active fund raising by the public for the Charity and to raise awareness of asthma
Year(s) Of Engagement Activity 2007,2008,2009
 
Description Established All Party Parliamentary Group on Allergy 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Primary Audience Policymakers/politicians
Results and Impact NASG has founded this Group to interact with parliamentarians over improved allergy provision

Allergy now recognised as a public health problem.
Year(s) Of Engagement Activity 2007,2008,2009
 
Description Established United Kingdom Respiratory Research Collaborative. 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Primary Audience Health professionals
Results and Impact A multiproffesional interaction to promote greater lung-related research in the UK (Founding Chair)

Since 2005 3-fold increase in success rate of lung research funding including MRC.
Year(s) Of Engagement Activity 2006,2007,2008,2009
 
Description Founded the National Allergy Strategy Group 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Primary Audience Public/other audiences
Results and Impact Created a unique Group for proffessionals (BSACI) and charities (Allergy UK, the Allergy Alliance, Anaphylaxis Campaign) to join forces to promote better allergy provisionin the UK

House of Lords S & T Committee Review of Allergy Services and formation of a Commissioning Group.
Year(s) Of Engagement Activity 2006,2007,2008,2009
 
Description MP visits to the laboratory 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Primary Audience Policymakers/politicians
Results and Impact Our local MPs have visited our laboratories on a number of occasions.

Representation of views in Parliament.
Year(s) Of Engagement Activity 2007,2008
 
Description Medicine and Me Conferences at RSM 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Primary Audience Public/other audiences
Results and Impact I have participated actively in 3 RSM Patient Medicine and Me Conferences (Asthma, Allergy, CFS)

Greater awareness of the diseases and their management.
Year(s) Of Engagement Activity 2007,2008,2009
 
Description Multiple interactions with the local and national press 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Primary Audience Media (as a channel to the public)
Results and Impact I am frequently contacted by the press, radio and TV for interviews relating to asthma and allergy.

Publication in the lay press and attraction of funding to our charity AAIR
Year(s) Of Engagement Activity 2006,2007,2008,2009,2010
 
Description President of the British Thoracic Society 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Primary Audience Health professionals
Results and Impact As President of the BTS I promulgated research findings and promoted lung research to many different professionals.

Greater awareness of lung diseases
Year(s) Of Engagement Activity 2006